From IT Expense to Revenue Driver: How CMS NTAP Activates the Clinical AI Commercial Flywheel
Dr. Dereck Mush, MD, MBA
Bayesian Health
FDA-cleared continuous AI sepsis monitor with a dedicated Medicare add-on payment.
What they do
Bayesian Health builds real-time clinical AI that flags patients at risk of sepsis earlier inside existing hospital workflows. Its sepsis flagging device received FDA Breakthrough designation and FDA clearance in April 2026, and was approved for a Medicare New Technology Add-on Payment under the CMS FY 2027 inpatient rule, effective October 1, 2026. Founder and CEO Suchi Saria, PhD, leads the company.
The record
- Vertical
- Clinical AI & Documentation
- Sub-segment
- Real-time clinical decision support
- Product type
- Software as a medical device
- Stage
- Private
- Headquarters
- New York, NY
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Clinical AI & Documentation
Related on The Signal
Dr. Dereck Mush, MD, MBA
The End of Phase-Gated Trials: How ARPA-H's SURPASS Program Reengineers Biomedical R&D
Dr. Dereck Mush, MD, MBA
Who Is Liable When AI Clinical Decision Support Gives Bad Advice?
Dr. Dereck Mush, MD, MBA
Healthcare AI Has an ROI Problem: Here Is What the Evidence Actually Shows
Dr. Dereck Mush, MD, MBA